Sulphasalazine in psoriatic arthritis: a double-blind placebo-controlled study.

@article{Farr1990SulphasalazineIP,
  title={Sulphasalazine in psoriatic arthritis: a double-blind placebo-controlled study.},
  author={M M Farr and George D Kitas and Linda Waterhouse and Ronald W Jubb and D D Felix-Davies and Paul A. Bacon},
  journal={British journal of rheumatology},
  year={1990},
  volume={29 1},
  pages={46-9}
}
Sulphasalazine (SASP) is now accepted as an effective slow-acting antirheumatic drug for treating active rheumatoid arthritis (RA), but has not been previously evaluated in psoriatic arthritis. An earlier open study suggested that it was well tolerated and potentially beneficial. The present double-blind placebo-controlled trial of 30 patients has now confirmed its efficacy. Greater improvement occurred in those patients on active treatment than on placebo, with more benefit being detected in… CONTINUE READING